Literature DB >> 12147323

Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice.

Amelia Marutle1, Christina Unger, Ewa Hellström-Lindahl, Jun Wang, Jukka Puoliväli, Heikki Tanila, Agneta Nordberg, Xiao Zhang.   

Abstract

The binding sites of nicotinic acetylcholine receptor (nAChR) subtypes were measured in the parietal cortex and hippocampus of transgenic mice carrying mutant human APPswe and presenilin 1 (PS1) genes (APPswe/PS1 mice) between the ages of 3 weeks and 17 months. Soluble and insoluble beta-amyloid peptide (Abeta1-40 and Abeta1-42) levels were investigated in parallel. No significant differences in binding sites of [(3)H]cytisine (alpha4beta2 nAChRs) and [(125)I]alpha-bungarotoxin (alpha7 nAChRs) were observed in APPswe/PS1 mice and wild-type control mice at any age studied. At three weeks of age, soluble Abeta1-40 was detectable in the parietal cortex and hippocampus of APPswe/PS1 mice, whereas Abeta1-42 was detectable from 12 months of age. A pronounced increase in insoluble Abeta1-42 was observed between 3 weeks and 17 months compared with that of insoluble Abeta1-40 in both brain regions, indicating a shift that favors accumulation of Abeta1-42 in older APPswe/PS1 mice. The findings indicate that elevated Abeta levels in the brains of APPswe/PS1 mice do not alter the number of alpha4beta2 and alpha7 receptors, the two major brain nAChR subtypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147323     DOI: 10.1016/s0304-3940(02)00546-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?

Authors:  M Colaianna; P Tucci; M Zotti; M G Morgese; S Schiavone; S Govoni; V Cuomo; L Trabace
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

3.  Nicotine prevents synaptic impairment induced by amyloid-β oligomers through α7-nicotinic acetylcholine receptor activation.

Authors:  Nibaldo C Inestrosa; Juan A Godoy; Jessica Y Vargas; Macarena S Arrazola; Juvenal A Rios; Francisco J Carvajal; Felipe G Serrano; Ginny G Farias
Journal:  Neuromolecular Med       Date:  2013-07-11       Impact factor: 3.843

4.  Accumulation of human full-length tau induces degradation of nicotinic acetylcholine receptor α4 via activating calpain-2.

Authors:  Yaling Yin; Yali Wang; Di Gao; Jinwang Ye; Xin Wang; Lin Fang; Dongqin Wu; Guilin Pi; Chengbiao Lu; Xin-Wen Zhou; Ying Yang; Jian-Zhi Wang
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

5.  Trans ε viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model.

Authors:  Martial Caillaud; Jérôme Guillard; Damien Richard; Serge Milin; Damien Chassaing; Marc Paccalin; Guylène Page; Agnès Rioux Bilan
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

Review 6.  Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.

Authors:  Steven D Buckingham; Andrew K Jones; Laurence A Brown; David B Sattelle
Journal:  Pharmacol Rev       Date:  2009-03-16       Impact factor: 25.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.